公开(公告)号：US20220241311A1

公开(公告)日：2022-08-04

申请号：US16973210

申请日：2019-06-14

Applicant: Mayo Foundation for Medical Education and Research ,  VIB vzw ,  Katholieke Universiteit Leuven, K.U. Leuven R&D

Inventor： Eva Morava-Kozicz ,  Tamas Kozicz ,  Bart Ghesquière

IPC: A61K31/7072 ,  A61P21/00

Abstract: This document provides methods and materials involved in treating congenital disorders of glycosylation (CDGs). For example, methods for using a composition including one or more uridine diphosphate (UDP)—sugars to treat a mammal (e.g., a human) having a CDG are provided.

公开(公告)号：US20220220180A1

公开(公告)日：2022-07-14

申请号：US17653554

申请日：2022-03-04

Applicant: Babraham Institute ,  VIB VZW ,  Katholieke Universiteit Leuven, K.U. Leuven R&D

Inventor： Matthew HOLT ,  Adrian LISTON ,  James DOOLEY

IPC: C07K14/55 ,  A61K35/17 ,  C12N15/86

Abstract: The invention relates to a method of expanding a population of regulatory T cells in a tissue or organ of a subject, wherein said method comprises administration of IL-2 and a targeting moiety specific for said tissue or organ, and wherein said tissue or organ is the central and/or peripheral nervous system. The invention further relates to populations of regulatory T cells produced according to the method and the production of said population in vivo. Also provided is a pharmaceutical composition comprising IL-2 and a targeting moiety as defined herein as well as a method of treating a disease or disorder mediated by inflammation or for the reduction of inflammation which comprises the methods defined herein or administration of a pharmaceutical composition as defined herein.

公开(公告)号：US20220033448A1

公开(公告)日：2022-02-03

申请号：US17402016

申请日：2021-08-13

Applicant: VIB VZW ,  VRIJE UNIVERSITEIT BRUSSEL ,  KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D ,  UNIVERSITEIT GENT

Inventor： Joost Schymkowitz ,  Frederic Rousseau

IPC: C07K14/40 ,  A61L31/16 ,  A61L29/16 ,  A61L31/08 ,  A61L27/00

Abstract: The present application belongs to the field of functional peptides and more particularly to the field of controlled protein aggregation. The invention discloses molecules of a peptide structure as defined in the claims and methods of using such molecules for therapeutic applications and for diagnostic uses, as well as in other applications such as in the agbio field and in industrial biotechnology. The molecules can be used for curing and/or stabilizing infections such as bacterial,fimgal and viral diseases, but are also useful in non-infectious human and veterinary diseases. The molecules can also be used for the detection of protein biomarkers and for the prognosis and diagnosis of a variety of diseases.

公开(公告)号：US10041126B2

公开(公告)日：2018-08-07

申请号：US14374869

申请日：2013-01-28

Applicant: VIB VZW ,  Life Sciences Research Partners VZW ,  Katholieke Universiteit Leuven, K.U.Leuven R&D

Inventor： Massimiliano Mazzone

IPC: C12Q1/68 ,  C07K16/00 ,  G01N33/574 ,  C12Q1/6886

Abstract: The disclosure relates to the field of biomarkers to diagnose a disease, more particularly to the field of biomarkers to diagnose cancer, and most particularly to colorectal cancer. Specifically, these biomarkers are expressed in monocytes of a subject, particularly circulating monocytes, as can be isolated from peripheral blood. The markers are particularly useful for early detection of cancer.

公开(公告)号：US09969748B2

公开(公告)日：2018-05-15

申请号：US15318422

申请日：2015-06-11

Applicant: UCB Biopharma SPRL ,  Katholieke Universiteit Leuven, K.U. Leuven R&D

Inventor： Daniel James Ford ,  Qiuya Huang ,  Judi Charlotte Neuss ,  James Thomas Reuberson ,  Bart Vanderhoydonck

IPC: A61K31/519 ,  A01N43/90 ,  C07D498/04 ,  C07D487/04 ,  C07D495/04

CPC classification number: C07D498/04 ,  A61K31/519 ,  C07D487/04 ,  C07D495/04

Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

公开(公告)号：US09951058B2

公开(公告)日：2018-04-24

申请号：US15433536

申请日：2017-02-15

Applicant: Korea Research Institute of Chemical Technology ,  Katholieke Universiteit Leuven K.U. Leuven R & D

Inventor： Young Sik Jung ,  Soo Bong Han ,  Chong-Kyo Lee ,  Hae Soo Kim ,  Jin Soo Shin ,  Johan Neyts ,  Hendrik Jan Thibaut ,  Yashwardhan Radhamohan Malpani

IPC: C07D417/12 ,  C07D307/93 ,  C07D405/12 ,  C07D409/12 ,  C07D407/12 ,  C07D413/12

CPC classification number: C07D417/12 ,  C07D307/93 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12

Abstract: The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

公开(公告)号：US09890133B2

公开(公告)日：2018-02-13

申请号：US15189771

申请日：2016-06-22

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D

Inventor： Young Sik Jung ,  Chong Kgo Lee ,  Hae Soo Kim ,  Hee Chun Jeong ,  Pil Ho Kim ,  Soo Bong Han ,  Jin Soo Shin ,  Johan Neyts ,  Hendrik Jan Thibaut

IPC: C07D307/93 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04 ,  C07D487/04 ,  C07D209/94 ,  C07D405/04 ,  C07D407/12 ,  C07D417/12 ,  C07C233/32 ,  C07D413/12 ,  C07D491/048 ,  C07F9/655

CPC classification number: C07D307/93 ,  C07C233/32 ,  C07D209/94 ,  C07D405/04 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07F9/65517

Abstract: Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

公开(公告)号：US09833423B2

公开(公告)日：2017-12-05

申请号：US15098972

申请日：2016-04-14

Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D

Inventor： Young Sik Jung ,  Chong Kgo Lee ,  Ihl Young Choi ,  Hae Soo Kim ,  Phil Ho Kim ,  Soo Bong Han ,  Johan Neyts ,  Hendrik Jan Thibaut

IPC: A61K31/122 ,  A61K31/435 ,  C07D221/04 ,  C07C49/747 ,  C07C271/24 ,  C07C271/44 ,  C07C271/64 ,  C07C275/26 ,  C07C275/64 ,  C07C205/45 ,  C07C323/22 ,  C07C225/20 ,  C07C225/22 ,  C07C233/32 ,  C07C233/33 ,  C07C233/41 ,  C07C233/43 ,  C07C233/61 ,  C07C233/76 ,  C07C247/14 ,  C07C69/16 ,  C07C69/18 ,  C07C69/28 ,  C07C69/54 ,  C07C69/618 ,  C07C69/63 ,  C07C69/738 ,  C07C69/78 ,  C07C49/753 ,  C07D215/20 ,  C07D213/65 ,  C07C45/00 ,  C07C67/00 ,  C07C69/12 ,  C07C69/22 ,  C07C69/736 ,  C07C269/00 ,  C07C49/755 ,  C07C67/08 ,  C07C231/02 ,  C07C271/12

CPC classification number: A61K31/122 ,  A61K31/435 ,  C07C45/00 ,  C07C49/747 ,  C07C49/753 ,  C07C49/755 ,  C07C67/00 ,  C07C67/08 ,  C07C69/12 ,  C07C69/16 ,  C07C69/18 ,  C07C69/22 ,  C07C69/28 ,  C07C69/54 ,  C07C69/618 ,  C07C69/63 ,  C07C69/736 ,  C07C69/738 ,  C07C69/78 ,  C07C205/45 ,  C07C225/20 ,  C07C225/22 ,  C07C231/02 ,  C07C233/32 ,  C07C233/33 ,  C07C233/41 ,  C07C233/43 ,  C07C233/61 ,  C07C233/76 ,  C07C247/14 ,  C07C269/00 ,  C07C271/12 ,  C07C271/24 ,  C07C271/44 ,  C07C271/64 ,  C07C275/26 ,  C07C275/64 ,  C07C323/22 ,  C07C2601/02 ,  C07C2602/08 ,  C07D213/65 ,  C07D215/20 ,  C07D221/04

Abstract: Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

公开(公告)号：US09809808B2

公开(公告)日：2017-11-07

申请号：US13061053

申请日：2009-08-25

Applicant: Yves Briers ,  Rob Lavigne ,  Guido Volckaert

Inventor： Yves Briers ,  Rob Lavigne ,  Guido Volckaert

IPC: C12N9/52 ,  C12N9/36 ,  A61K38/00

CPC classification number: C12N9/2462 ,  A61K38/00 ,  C12N9/52 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481

Abstract: The present invention relates to endolysin variants comprising an endolysin to which a peptide stretch with membrane or LPS disrupting activity is fused. Moreover, the present invention relates to nucleic acid molecules encoding said modified endolysin variant, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to a method for producing said endolysin variant. Further, the present invention relates to said modified endolysin variant for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said endolysin variant as a diagnostic means in medicinal, food or feed or environmental diagnostic. Finally, the present invention relates to a pharmaceutical composition comprising said modified endolysin variant.

公开(公告)号：US09434722B2

公开(公告)日：2016-09-06

申请号：US14060563

申请日：2013-10-22

Applicant: Katholieke Universiteit Leuven, K.U.Leuven R&D ,  reMYND

Inventor： Gerard Griffioen ,  Tom Van Dooren ,  Veronica Rojas De La Parra ,  Arnaud Marchand ,  Sara Allasia ,  Amuri Kilonda ,  Patrick Chaltin

IPC: C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

CPC classification number: A61K31/4045 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/635 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Abstract translation: 本发明提供了新的化合物和用作药物的新化合物，更特别是用于预防或治疗神经变性疾病，更具体地，某些神经系统疾病，例如统称为tau蛋白病的病症，以及细胞毒性α-突触核蛋白淀粉样变性特征的病症 。 本发明还涉及所述新化合物在制备可用于治疗这种神经变性疾病的药物中的用途。 本发明还涉及包含所述新化合物的药物组合物和制备所述新化合物的方法。